Development of Silica-Immobilized Vaccines for Improving Thermo-Tolerance and Shelf-Life.
IpaD protein
mesoporous silica
shigellosis
vaccines
Journal
Kansas journal of medicine
ISSN: 1948-2035
Titre abrégé: Kans J Med
Pays: United States
ID NLM: 101581958
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
02
2020
accepted:
10
02
2020
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
epublish
Résumé
It is estimated that 50% of vaccines produced annually are wasted because effectivity is dependent on protein structure and heat exposure disrupts the intermolecular interactions that maintain this structure. Since 90% of vaccines require a temperature-controlled supply chain, it is necessary to create a cold chain system to minimize vaccine waste. We have developed a more sustainable technology via the adsorption of Invasion Plasmid Antigen D (IpaD) onto mesoporous silica gels, improving the thermal stability of protein-based therapeutics. The solution depletion method using UV-Vis was utilized to study the adsorption of IpaD onto silica gels. The silica-IpaD complex is heated above the denaturing temperature of the protein and then the IpaD is removed using N,N-Dimethyldodecylamine N-oxide (LDAO) and their secondary structure is tested using circular dichroism (CD). Pore diameter, pore volume and surface area were characterized for seven different silica gels. Silica gels designated as 6389, 6378, and 6375 had an adsorption percentage above 95% at pore volumes of 2.2, 2.8 and 3.8 cm We have successfully increased the thermo-tolerance for IpaD using mesoporous silica and continue to further optimize mesoporous silica's physiochemical properties to improve adsorption and desorption yields.
Types de publication
Journal Article
Langues
eng
Pagination
6-9Informations de copyright
© 2020 The University of Kansas Medical Center.
Références
Bull World Health Organ. 1999;77(8):651-66
pubmed: 10516787
Infect Immun. 2012 Mar;80(3):1222-31
pubmed: 22202122
Arch Biochem Biophys. 1998 Dec 1;360(1):121-34
pubmed: 9826437
J Control Release. 2001 Jun 15;73(2-3):233-44
pubmed: 11516501
J Immunol. 2000 Feb 15;164(4):2221-32
pubmed: 10657678
J Infect Dis. 1989 Jun;159(6):1126-8
pubmed: 2656880
Infect Immun. 1996 Oct;64(10):4074-7
pubmed: 8926071
Anal Chem. 2012 Nov 6;84(21):9089-95
pubmed: 23009597
Langmuir. 2004 Aug 3;20(16):6800-7
pubmed: 15274588
Biophys J. 1985 Mar;47(3):411-4
pubmed: 3978211
J Biosci Bioeng. 2001;91(3):233-44
pubmed: 16232982
ACS Nano. 2012 Jul 24;6(7):6356-63
pubmed: 22725630
Vaccine. 2010 Feb 10;28(6):1642-54
pubmed: 19932216
Vaccine. 1995 Apr;13(5):495-502
pubmed: 7639017
Infect Immun. 2009 Jul;77(7):2754-61
pubmed: 19433542
J Biol Chem. 2007 Feb 9;282(6):4035-44
pubmed: 17077085
Sci Rep. 2017 Apr 24;7:46568
pubmed: 28436442
Biochemistry. 2006 Aug 1;45(30):9219-27
pubmed: 16866368
J Control Release. 2011 Jun 30;152(3):329
pubmed: 21600940
Vaccine. 1997 Aug-Sep;15(12-13):1459-65
pubmed: 9302761
J Clin Microbiol. 1993 Feb;31(2):454-7
pubmed: 8432838
Infect Immun. 2004 Feb;72(2):923-30
pubmed: 14742537
Infect Immun. 2006 Aug;74(8):4391-400
pubmed: 16861624